18 April, 2016
Chordate Medical has been granted an EU patent covering a system for affecting the autonomous nervous system of a person by vibrational stimulation. We continue to strengthen our global IP protection of the technology that forms the base for current and future products. Our IP insurance enable us to protect our patents from infringement
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.